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PREFACE 
 
This dissertation is presented in a manuscript format. The findings of the study are presented in 
chapter 2, in manuscript format as required by the regulations of the University of KwaZulu-Natal. 
The manuscript will be submitted for publication in the South African Medical Journal (SAMJ). The 
reference list is cited according to the instructions for authors as required by the SAMJ. A complete 
reference list is included at the end of every chapter and according to the reference style of the 
University of KwaZulu-Natal.  
 
The dissertation consists of three chapters as follows: 
• Chapter 1: provides an introduction to the study as well as the aims, objectives, literature 
review and a brief overview of the methodology.  
• Chapter 2: consists of the results, discussion and conclusion written in a manuscript format.  
• Chapter 3: provides the general conclusions, recommendations, limitations and strengths of 
the study.  
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ABSTRACT 
 
Background and Aim 
Antibiotics are one of the most troublesome classes of drugs contributing to adverse drug reactions. 
These adverse drug reactions are generally under reported. This study aimed to evaluate the adverse 
drug reactions associated with antibiotic use in a public sector hospital.  
 
Methods  
A prospective, quantitative study was carried out using adverse drug reaction reports collected from a 
public sector hospital in South Africa, for the period 01 July 2016 – 30 September 2016. All the 
adverse drug reaction reports attributed to use of antibiotics were included in the study. The patient’s 
age, gender, weight, antibiotic prescribed, dose of antibiotic, route of administration of the antibiotic, 
adverse drug reaction experienced and action taken regarding the adverse drug reaction was extracted 
from the adverse drug reaction report. A descriptive and inferential analysis was carried out using 
SPSS (version 24) to determine the strength of the relationships (Pearson Chi Square test) between 
different variables. 
  
Results 
A total of 10 adverse drug reaction reports were collected during the 3 month period from which 8 
were related to antibiotic use (80%). Adverse drug reactions associated with antibiotic use were 
experienced mostly by female patients (n=6, 75%). Adverse drug reactions were reported for 
Amphoteracin B (n=3), Amoxicillin (n=1), Cefazolin (n=1), Lopinavir/Ritonavir combination (n=1), 
Metronidazole (n=1) and Tenofoir/Emtricitrabine/Efavirenz combination (n=1). Of the 8 adverse drug 
reactions, 7 required intervention to prevent permanent damage/disability. There were 2 serious 
adverse drug reactions; 1 required hospitalization and the other prolonged hospital stay; the remaining 
adverse drug reactions were classified as non-serious.  
 
Discussion and Conclusion  
Antibiotic related adverse drug reactions constituted 80% of all adverse drug reactions reported in a 
single hospital. The impact of adverse drug reactions associated with antibiotic use in the public 
hospital ranged from treatment to manage the adverse drug reaction to hospitalization and the 
prolongation of hospital stay. This study provides useful information on the current status of adverse 
drug reactions related to antibiotic use in the public sector in South Africa, and indicates the need for 
adverse drug reaction reporting in hospitals to ensure safety of medicines and better treatment 
outcomes. 
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KEYWORDS 
 
Pharmacovigilance is defined as the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem. 
 
Adverse drug reaction means a response to a medicine in humans or animals, which is noxious and 
unintended, including lack of efficacy, and which occurs at any dosage and can also result from 
overdose, misuse or abuse of a medicine. 
 
An adverse drug reaction report is a detailed record of all relevant data associated with the use of a 
medicine in a subject or patient. 
 
Healthcare professionals are medical practitioners, pathologists, dentists, pharmacists, nurses, and 
other healthcare professionals, including allied healthcare professionals. 
 
Antibiotics are (for the purpose of this study) antibacterials, antivirals, antifungals, antituberculars, 
antimalarials and anthelmintics. 
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CHAPTER 1 
INTRODUCTION 
An adverse drug reaction is a response to a medicine in humans or animals, which is noxious and 
unintended, and which occurs at any dosage. 1 It can also result from an overdose, misuse or abuse of 
a medicine. It is, by its very nature, undesirable, untoward, or detrimental to the healthcare process or 
to the patient. Adverse drug reactions may be mild, moderate or severe. A serious adverse drug 
reaction at any dose may: 1) result in death, 2) be life threatening, 3) require patient hospitalization, 4) 
prolong existing hospitalization, or 5) cause a congenital anomaly/birth defect. A reportable adverse 
drug reaction requires the following minimum information: An identifiable source (reporter) of the 
information, an identifiable patient, suspected product(s) and suspected reaction(s). 
 
According to the World Health Organization policy on ensuring the safe use of medicines (2004), 
“Pharmacovigilance is the science and activities relating to the detection, assessment, understanding 
and prevention of adverse or any other drug related problems”. Pharmacovigilance relies on: 1) 
collecting information from reliable scientific resources such as healthcare professionals, consumers 
and journals; 2) classifying and analyzing the information; and 3) circulating its contents as well as 
any action taken on a specific drug to all healthcare sectors. The aims of pharmacovigilance are to 
improve the safety of medicines so as to improve patient care and public health as well as assess the 
risk of the use of medicines. 
 
Challenges of adverse drug reaction reporting include: under-detection (the inability of healthcare 
professionals in identifying adverse drug reactions) and under-reporting (healthcare professionals 
presume that adverse drug reaction reporting may indicate incompetence). Many factors are 
associated with under-reporting of adverse drug reactions among health care professionals. These 
factors have been broadly classified in 2009 by Oshikoya et al,2 as personal and professional 
characteristics of health care professionals, and their knowledge and attitudes to reporting. These 
factors include:  
• attitudes relating to professional activities (financial incentives: rewards for reporting; legal 
aspects: fear of litigation or enquiry into prescribing costs; and ambition to compile or publish 
a personal case series)  
• problems associated with adverse drug reaction related knowledge and attitudes 
(complacency: the belief that very serious adverse drug reactions are well documented by the 
time a drug is marketed; diffidence: the belief that reporting an adverse drug reaction would 
only be done if there was certainty that it was related to the use of a particular drug; 
indifference: the belief that the single case an individual doctor might observe could not 
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contribute to medical knowledge; and ignorance: the believe that it is only necessary to report 
serious or unexpected adverse drug reactions) 
• excuses made by professionals (lethargy: the procrastination and disinterestedness in 
reporting or lack of time to find a report card and other excuses).  
 
With increased access to newly introduced essential drugs, there is a greater need to monitor and 
promote their safety and effectiveness. Benefits of adverse drug reaction reporting include: improved 
quality of care, ensuring patient safety, reduced drug-related problems, better treatment outcomes and 
changes in drug labelling or removal of medicines from the market.3  
 
1.1 Problem and significance of work  
The most troublesome classes of drugs contributing to adverse drug reactions are antibiotics; these are 
responsible for the recorded adverse effects in approximately 16% of cases4, therefore 
pharmacovigilance of antibiotics is essential to maintain the safety of antibiotics. Granowitz and 
Brown5 state that although adverse events seem to occur in a small proportion of antibiotic courses, 
the frequency of antibiotic use makes them account for 23% of all adverse events recorded. Antibiotic 
related adverse drug reactions are generally under reported, this may be due to the lack of training of 
healthcare workers regarding adverse drug reaction reporting or the lack of public awareness on the 
need to report suspected adverse drug reactions.  
Adverse drug reactions related to antibiotics may result in hospitalization, extended hospital stay or 
death. They may even occur in hospital due to improper prescribing or due to risk factors like age and 
multiple drug use. Shamma et al4 identified an increase in healthcare cost associated with antibiotic 
adverse drug reactions, due to increased length of hospital stay and the need of interventions including 
stopping the antibiotic and treating the adverse reaction; concluding that periodic reporting of adverse 
drug reactions should be done in order to increase drug safety. Hospital-based adverse drug reaction 
monitoring and reporting programs therefore aim to identify and quantify the risks associated with the 
use of drugs provided in a hospital setting. This information may be useful in identifying and 
minimizing preventable adverse drug reactions and may enhance the ability of prescribers to manage 
adverse drug reactions more effectively.6 
This study will describe adverse drug reactions related to antibiotic use in a public sector hospital. 
This information will be useful in providing the current status of the problem in public hospitals, and 
also identify if there is a need to address this. The results of this study will also hopefully encourage 
health care professionals to report adverse drug reactions and contribute to the development of 
strategies for pharmacovigilance at public sector hospitals, which will improve the quality of adverse 
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drug reaction monitoring and reporting to ensure safer antibiotic use in hospitals.  
 
1.2 Literature review 
 
1.2.1 Adverse drug reactions and antibiotic use 
In many countries adverse drug reactions rank among the top 10 leading causes of mortality.4 In 
Europe, adverse drug reactions cause a considerable amount of morbidity and mortality. It has been 
estimated that approximately 5 % of all hospital admissions are caused by adverse drug reactions, that 
5 % of hospitalized patients will experience an adverse drug reaction during their hospital stay, and 
that approximately 197,000 deaths per year are due to adverse drug reactions.7 In a South African 
survey, adverse drug reactions were the cause of admission for 6.3% of adults admitted to medical 
wards, and an additional 6.3% of inpatients developed adverse drug reactions during their hospital 
stay. Recently, adverse drug reactions were implicated in 16% of deaths in the medical wards of four 
South African hospitals.8 
Antibiotics are among the most commonly prescribed drugs in hospitals and they account for 20% to 
50% of drug costs. Several studies showed antibiotics as one of the drug groups causing more adverse 
drug reactions9 than other drugs. An extensive drug monitoring study was conducted amongst adult 
inpatients taking antibiotics in the city of Maringá, Southern Brazil, from September 2002 to February 
2003. The study found that an inadequate knowledge on antibiotics or lack of information about the 
patient at the time of prescription were the major factors involved in the occurrence of adverse 
events.9 Evaluating the dose, route and duration of treatment when prescribing antibiotics is 
significant because any of those factors can increase the occurrence of adverse drug reactions. 
In a prospective study Lobo et al6 found antibiotics (vancomycin and ceftriaxone) to be among the 
most common drugs causing adverse drug reactions. These antibiotics required intervention and 
increased the hospital stay. Several studies conducted over the past years suggest a high direct 
relationship between antibiotics and specific adverse effects experienced. Viswanathan et al10 
suggested that there is a potential relationship between linezolid use and hypoglycaemia, while 
Richard Frothingham11 identified glucose homeostasis abnormality (GHA) as an adverse drug 
reaction of gatifloxacin. Lawrence12 delineated the quantity and outcomes of patients who developed 
serotonin toxicity while undergoing concurrent therapy with linezolid and medications that increase 
CNS serotonin concentrations.  
Antibiotics are one of the most commonly prescribed drugs in hospitals. The implementation 
of adverse event monitoring and notification programs in hospital settings is an important 
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action for the prevention of adverse drug reactions associated with antibiotic use.9 
1.2.2 Importance of adverse drug reaction reporting in hospitals 
Adverse drug reactions have a major impact on public health by imposing a considerable economic 
burden on the society and the already stretched healthcare systems,2 therefore post marketing 
surveillance of drugs is very important in analysing and managing the risks associated with drugs 
once they are available for use by the general population. According to Tumwikirize et al13 when 
studying adverse drug reactions’ contribution to patient morbidity and hospitalization in Africa, they 
found that 4.5–8.4% of all hospital admissions were related to adverse drug reactions, 1.5–6.3% of 
patients were admitted as a direct result of adverse drug reactions; and 6.3–49.5% of all hospitalized 
patients developed adverse drug reactions.  
Adverse drug reactions are recognized as a common cause of hospital admissions, and they constitute 
a significant economic burden for hospitals. The proportion of patients admitted with adverse drug 
reactions ranges from approximately 2.0 to 21.4%, whereas between 1.7 and 25.1% of inpatients are 
reported to have developed an adverse drug reaction during their hospital stay.6 Adverse drug reaction 
reporting is essential in a hospital setting so as to ensure the safety of drugs administered to patients, 
improving the quality of care, minimizing the length of hospital stay, health care costs and the 
interventions required. 
Reports of adverse drug reactions have become an important component of monitoring and evaluation 
activities performed in hospitals to ensure drug safety.6 Hospital-based adverse drug reaction 
monitoring and reporting programs aim to identify and quantify the risks associated with the use of 
drugs provided in a hospital setting.6 Thus periodic reporting of adverse drug reactions should 
therefore be done to increase drug safety.4  
Two different methods of collecting adverse drug reaction reports are available. One is traditional 
adverse drug reaction reporting, which is called "spontaneous reporting." The other is "active 
surveillance," using a phone-structured interview, ward rounds and chart review, or computer 
monitoring. Active surveillance, as opposed to spontaneous pharmacovigilance systems, can be 
defined as the periodic collection of case reports from healthcare data systems. Active surveillance 
systems, such as ward rounds associated with chart review increase the rate of adverse drug reaction 
detection and detect more serious adverse drug reactions in a hospital setting.14 
Spontaneous pharmacovigilance systems are not as effective as active surveillance due to under-
reporting and insufficient clinical information; thus, active surveillance programs should be 
implemented in the hospital setting to ensure patient safety and improve the quality of care. The 
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implementation of adverse event monitoring and notification programs in hospital settings is an 
important action for the prevention of these adverse drug reactions. These programs promote active 
surveillance and encourage their documentation and notification.9 A comprehensive systems 
perspective addresses the need for both active and passive approaches to identify medicines-related 
problems, effective mechanisms to communicate medicine safety information to health care 
professionals and the public, collaboration among a wide range of partners and organizations, and 
incorporation of pharmacovigilance activities at all levels of the health system.3 
 
1.3 Aim and Objectives 
 
The aim of this study was to evaluate adverse drug reactions associated with antibiotic use in a public 
sector hospital in South Africa. 
Specific objectives were to determine the following: 
1.3.1 The number of adverse drug reactions associated with antibiotic use over a 3 month period. 
1.3.2 Identification of the antibiotic associated with the highest number of adverse drug reactions.  
1.3.3 Clinical profile of antibiotics associated with adverse drug reactions including indication and 
route of administration. 
1.3.4 Classification of adverse drug reactions according to severity. 
1.3.5 Classification of adverse drug reactions according to action taken. 
 
1.4 Theoretical framework 
A prospective study was performed on adverse drug reactions experienced with antibiotic use in a 
public sector hospital over a three month period. At the onset of the study clinical meetings with 
hospital healthcare professionals were held to raise awareness of adverse drug reaction monitoring. 
This has not been done previously in this hospital. The importance of adverse drug reaction 
monitoring was highlighted and attendees consisting of doctors and nurses were encouraged to report 
all suspected adverse drug reactions to a pharmacist in the hospital using an adverse drug reaction 
reporting form.  
Admissions due to adverse drug reactions related to antibiotic use, as well as those occurring during 
the hospital stay were included in the study. For patients where an adverse drug reaction was 
suspected, monitoring was done by assessing the progress of the patient daily throughout their 
hospital stay after action was taken to resolve the adverse drug reaction.  
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The suspected adverse drug reactions were carefully analysed and documented. All relevant data was 
recorded e.g. demographic information, indication for antibiotic usage, and routes of administration. 
Therapy given to treat the antibiotic adverse drug reactions was recorded and response noted. 
The severity of the adverse drug reaction was classified as serious or non-serious. Serious adverse 
drug reactions – (when the patient outcome was death, life threatening, required hospitalization, 
resulted in disability or a birth defect), and non-serious – (when the patient outcome was not death, 
not life threatening, did not require hospitalization, did not result in disability or cause a birth defect) 
were stated.  
 
1.5 Research methodology 
 
1.5.1 Study design 
A prospective quantitative study of adverse drug reaction reports associated with antibiotics collected 
between 01 July 2016 and 30 September 2016. 
 
1.5.2 Setting 
The study took place in a 150 bed public sector hospital, Mpumalanga, South Africa. 
 
1.5.3 Subjects/Participants 
In-patients (hospital patients).  
 
1.5.4 Sampling 
All adverse drug reaction reports were collected over the three month study period.  
 
1.5.5 Data collection/Methods 
The total number of admissions from 01 July 2016 to 30 September 2016 due to adverse drug 
reactions was recorded. The number of admissions due to adverse drug reactions related to antibiotics 
were calculated and compared to the total number of admissions due to adverse drug reactions. Patient 
demographics including; age, sex and weight were recorded.  
 
Adverse drug reactions associated with antibiotics were categorized as serious (when the patient 
outcome was death, life threatening, required hospitalization, prolonged hospitalization, disability or 
birth defect) and non-serious (when the patient outcome was not death, not life threatening, did not 
require hospitalization, did not prolong hospitalization, did not result in disability or a birth defect). 
Action taken to manage the adverse drug reaction was recorded. 
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1.5.6 Data analysis 
 
Variable Variable type Descriptive measures Analytical 
method/Statistical test 
Age Continuous Mean, median, mode, 
SD 
ANOVA 
Gender Categorical Mean, median, mode 
SD 
ANOVA 
Seriousness Ordinal 
 
Proportion Chi square 
Action taken 
 
Ordinal Proportion Chi square 
 
SPSS (computer software) was used for the statistical tests.  
 
1.5.7 Ethical approval 
Full ethical approval for the study was obtained from the Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal (BE255/16) – (ANNEXURE 1), and permission to use the hospital 
adverse drug reaction reports was obtained from the Mpumalanga Department of Health 
(ANNEXURE 2).  
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1.6 Chapter summary 
 
This chapter provided a background and rationale to the study. It also identifies the aim and objectives 
of the study and a brief overview of the methodology used in the study.  
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CHAPTER 2 
MANUSCRIPT FOR SUBMISSION AND PUBLICATION 
 
2.1 Introduction 
 
This chapter describes the general findings and discussion of the results of the study and is 
represented in the form of a manuscript titled “Evaluating adverse drug reactions associated 
with antibiotic use in a public sector hospital”. This manuscript will be submitted to the 
“South African Medical journal” (SAMJ) for publication. 
 
The journal instructions to the author can be viewed in ANNEXURE 3 or with the following 
link: 
http://www.samj.org.za/index.php/samj/about/submissions 
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2.2 Manuscript 
 
Evaluating adverse drug reactions associated with antibiotic use in a public sector 
hospital 
 
Nokuthemba Sibusiso Moyo, Frasia Oosthuizen* 
School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Private Bag 
X54001, Durban 4000, South Africa. 
 
*Corresponding author email: oosthuizenf@ukzn.ac.za  
 Contact number: 031-2607242    Fax: 031-2607907 
 
ABSTRACT 
 
Background and Aim 
Antibiotics are one of the most troublesome classes of drugs contributing to adverse drug 
reactions. These adverse drug reactions are generally under reported. This study aimed to 
evaluate the adverse drug reactions associated with antibiotic use in a public sector hospital.  
 
Methods  
A prospective, quantitative study was carried out using adverse drug reaction reports 
collected from a public sector hospital in South Africa, for the period 01 July 2016 – 30 
September 2016. All the adverse drug reaction reports attributed to the use of antibiotics were 
included in the study. The patient’s age, gender, weight, antibiotic prescribed, dose of 
antibiotic, route of administration of the antibiotic, adverse drug reaction experienced and 
action taken regarding the adverse drug reaction was extracted from the adverse drug reaction 
report. A descriptive and inferential analysis was carried out using SPSS (version 24) to 
determine the strength of the relationships (Pearson Chi Square test) between different 
variables. 
  
Results 
A total of 10 adverse drug reaction reports were collected during the 3 month period from 
which 8 were related to antibiotic use (80%). Adverse drug reactions associated with 
antibiotic use were experienced mostly by female patients (n=6, 75%). Adverse drug 
reactions were reported for Amphoteracin B (n=3), Amoxicillin (n=1), Cefazolin (n=1), 
Lopinavir/Ritonavir combination (n=1), Metronidazole (n=1) and 
Tenofoir/Emtricitrabine/Efavirenz combination (n=1). Of the 8 adverse drug reactions, 7 
required intervention to prevent permanent damage/disability. There were 2 serious adverse 
drug reactions; 1 required hospitalization and the other prolonged hospital stay; the remaining 
adverse drug reactions were classified as non-serious.  
 
 
Discussion and Conclusion  
Antibiotic related adverse drug reactions constituted 80% of all adverse drug reactions 
reported in a single hospital. The impact of adverse drug reactions associated with antibiotic 
use in the public hospital ranged from treatment to manage the adverse drug reaction to 
hospitalization and the prolongation of hospital stay. This study provides useful information 
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on the current status of adverse drug reactions related to antibiotic use in the public sector in 
South Africa, and indicates the need for adverse drug reaction reporting in hospitals to ensure 
safety of medicines and better treatment outcomes. 
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Background and Introduction 
 
An adverse drug reaction is a response to a medicine in humans or animals, which is noxious 
and unintended, and which occurs at any dosage.1 It can also result from an overdose, misuse 
or abuse of a medicine. It is, by its very nature, undesirable, untoward, or detrimental to the 
healthcare process or to the patient. Adverse drug reactions may be mild, moderate or severe. 
A serious adverse drug reaction at any dose may: 1) result in death, 2) be life threatening, 3) 
require patient hospitalization, 4) prolong existing hospitalization, or 5) cause a congenital 
anomaly/birth defect. A reportable ADR requires the following minimum information: An 
identifiable source (reporter) of the information, an identifiable patient, suspected product(s) 
and suspected reaction(s). 
 
According to the World Health Organization policy on ensuring the safe use of medicines 
(2004), “Pharmacovigilance is the science and activities relating to the detection, 
assessment, understanding and prevention of adverse or any other drug related problems”. 
Pharmacovigilance relies on: collecting information from reliable scientific resources such as 
healthcare professionals, consumers and journals; classifying and analyzing the information 
and circulating its contents as well as any action taken on specific drug to all healthcare 
sectors. The aims of pharmacovigilance are to improve the safety of medicines so as to 
improve patient care and public health as well as assess the risk of the use of medicines. 
 
Challenges of adverse drug reaction reporting include: under-detection (the inability of 
healthcare professionals in identifying adverse drug reactions) and under-reporting 
(healthcare professionals presume that adverse drug reaction reporting may indicate 
incompetence). With increased access to newly introduced essential drugs, there is a greater 
need to monitor and promote their safety and effectiveness. Benefits of adverse drug reaction 
reporting include: improved quality of care, ensuring patient safety, reduced drug-related 
problems, better treatment outcomes and changes in drug labelling or removal of medicines 
from the market.2  
 
The most troublesome classes of drugs contributing to adverse drug reactions are antibiotics; 
these are responsible for the recorded adverse effects in approximately 16% of cases.3 
Pharmacovigilance of antibiotics is essential to maintain the safety of antibiotics. Granowitz 
and Brown,4 state that although adverse events seem to occur in a small proportion of 
antibiotic courses, the frequency of antibiotic use makes them account for 23% of all adverse 
events recorded. Antibiotic related adverse drug reactions are generally under reported, this 
may be due to the lack of training of healthcare workers regarding adverse drug reaction 
reporting or the lack of public awareness on the need to report suspected adverse drug 
reactions.  
 
Adverse drug reactions related to antibiotics may result in hospitalization, extended hospital 
stay or death. They may even occur in hospital due to improper prescribing or due to risk 
factors like age and multiple drug use. Shamma et al3 identified an increase in healthcare cost 
associated with antibiotic adverse drug reactions, due to increased length of hospital stay and 
the need of interventions including stopping the antibiotic and treating the adverse reaction; 
concluding that periodic reporting of adverse drug reactions should be done in order to 
increase drug safety. Hospital-based adverse drug reaction monitoring and reporting 
programs therefore aim to identify and quantify the risks associated with the use of drugs 
provided in a hospital setting. This information may be useful in identifying and minimizing 
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preventable adverse drug reactions and may enhance the ability of prescribers to manage 
adverse drug reactions more effectively.5 
This study will describe adverse drug reactions related to antibiotic use in a public sector 
hospital. This information will be useful in providing the current status of the problem in 
public hospitals, and also identify if there is a need to address this. The results of this study 
will also hopefully encourage health care professionals to report adverse drug reactions and 
contribute to the development of strategies for pharmacovigilance in public sector hospitals, 
which will improve the quality of adverse drug reaction monitoring and reporting to ensure 
safer antibiotic use in hospitals.  
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Methods 
 
Study sample 
The study focused on antibiotic related adverse drug reactions reported in a 150 bed public 
sector hospital in Mpumalanga, South Africa over the stipulated time frame (01 July 2016 – 
30September 2016). A total of 10 adverse drug reaction reports were received, of which 8 
were analyzed according to the inclusion criteria of the study.  
 
The inclusion criteria encompassed adverse drug reaction reports associated with the use of 
antibiotics (for the purpose of this study - antibacterials, antivirals, antifungals, 
antitubercular, antimalarial and anthelmintics) that were submitted during 01 July 2016 – 30 
September 2016. The exclusion criteria includes adverse drug reaction reports that; 1) were 
incomplete, 2) adverse drug reactions reported for medicines other than antibiotics (e.g. anti-
hypertensive medicines) and 3) adverse drug reaction reports received out of the stipulated 
time frame.   
 
Only 8 adverse drug reaction reports met the criteria and were included for analysis. All of 
the results are based on information on the adverse drug reaction reporting forms completed 
by the health care professionals.  
 
Full ethical approval for the study was obtained from the University of KwaZulu-Natal, and 
permission to use the adverse drug reaction reports was obtained from the Mpumalanga 
Provincial Department of Health.  
 
Sampling, data collection and analysis 
The data in the form of adverse drug reaction reports was captured in Microsoft Office Excel. 
Data included patient demographics (age, gender, weight) and clinical data (antibiotic(s) that 
were involved, type of adverse drug reaction reported, intervention and patient outcome). 
Data was coded using numbers analysed using SPSS (version 24).  
 
Descriptive and inferential analyses were conducted. Descriptive analysis included 
information on frequencies, percentages, measures of central tendency (e.g. mean, median 
and mode), and measures of variability (e.g. range, standard deviation and variance). 
Inferential analysis was carried out to determine the strength of the relationships (Pearson Chi 
Square test) between different variables. A difference between variables with a p-value of 
less than 0.05 was considered to be statistically significant. Close attention was paid to the 
most prevalent types of adverse drug reactions, antibiotic(s) involved, and patient 
demographics in order to identify if some populations are more at risk of developing adverse 
drug reactions. 
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Findings 
 
Adverse drug reactions 
A total of 10 adverse drug reaction reports were received for the period 01 July – 30 
September 2016, 8 of these reports were linked to the use of antibiotics. 
 
Antibiotics associated with adverse drug reactions were identified as amphoteracin B (n=3), 
amoxicillin (n=1), metronidazole (n=1), cefazolin (n=1), lopinavir/ritonavir combination 
(n=1) and the tenofovir/emtricitrabine/efavirenz combination (n=1). 
 
Overview of patient demographics 
The majority of adverse drug reaction reports submitted were adverse drug reactions 
experienced by female patients n=6 (75%) as compared to male patients n=2 (25%). The 
mean weight of both males and females who experienced adverse drug reactions was 48.2± 
27.4kg and the mean age was 33.8 ± 26.7 years old. 
 
Adverse drug reaction reports were received as follows according to age groups: 0-14 n=3 
(37.5%); adults n=3 (37.5%), and ≥60 (geriatric) n=2 (25%). 
 
Analysis of Antibiotics related to patient demographics 
ADRs were reported for the following antibiotics: amphotericin B (n=3), metronidazole 
(n=1), cefazolin (n=1), amoxacillin (n=1) tenofovir/emtricitrabine/efavirenz combination 
(n=1) and lopinavir/ritonavir combination (n=1). 
 
Table 1: Adverse drug reactions reported in relation to the patient demographics  
 
Antibiotic Male Female 0-14 
years 
old 
30-
60years 
old 
>60years 
old 
Amphoteracin B 0 3 0 3 0 
Amoxicillin 1 0 1 0 0 
Cefazolin 0 1 0 0 1 
Lopinavir/Ritonavir 0 1 0 0 1 
Metronidazole 0 1 1 0 0 
Tenofovir/Emtricitrabine/Efavirenz 1 0 1 0 0 
 
 
Amphoteracin B caused adverse drug reactions in female patients only (n=3) as did 
metronidazole (n=1), cefazolin (n=1) and lopinavir/ritonavir combination. Amoxicillin 
caused an adverse drug reaction in a male patient only (n=1) as did 
tenofovir/emtricitrabine/efavirenz combination. 
 
In the 0-14 year age group amoxicillin (n=1), metronidazole (n=1), and 
tenofovir/emtricitrabine/efavirenz combination (n=1) were responsible for the adverse drug 
reactions. In the 30-60 year age group (n=3) of patients developed adverse drug reactions 
associated with the use of amphoteracin B. Patients who were ≥60 years old experienced 
adverse drug reactions caused by the use of cefazolin (n=1) and lopinavir/ritonavir 
combination (n=1). 
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Clinical profile of antibiotics associated with adverse drug reactions including indication 
and route of administration 
 
Table 2: Indication and route of administration of antibiotic 
 
Antibiotic  Indication 
 
Route of administration 
Amphoteracin B(n=3) Cryptococcal meningitis Intravenous 
 
Amoxicillin Malnutrition  Oral 
 
Cefazolin Infection Intravenous 
 
Lopinavir/Ritonavir Human 
Immunodeficiency Vius 
Oral 
 
Metronidazole Urinary tract infection Intravenous 
 
Tenofovir/Emtricitrabine/Efavirenz Human 
Immunodeficiency Vius  
Oral 
 
The intravenous route of administration was used for most antibiotics (n=5) where adverse 
drug reactions were reported. In only 3 cases antibiotics that were administered orally 
resulted in an adverse reaction. 
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Analysis of type adverse drug reactions experienced and seriousness 
 
Table 3: Type and seriousness of adverse drug reactions reported 
 
Antibiotic  Adverse drug reaction 
 
Seriousness 
Amphoteracin B Shivering  Non-serious 
 
Amphoteracin B Shivering, fever, swollen 
arm 
 
Serious (prolonged 
hospital stay) 
Amphoteracin B Lip sores Non-serious 
 
Amoxicillin Rash  Non-serious 
 
Cefazolin Facial oedema Non-serious 
 
Lopinavir/Ritonavir Vomiting Non-serious 
 
Metronidazole Vomiting  Non-serious 
 
Tenofovir/Emtricitrabine/Efavirenz Dizziness  Serious (required 
hospitalization) 
 
The reported adverse drug reactions and their associated antibiotics are described in Table 3. 
The most commonly reported adverse drug reaction associated with the use of antibiotics was 
shivering n=2 and vomiting (n=2). The other adverse drug reactions reported included: rash 
(n=1), dizziness (n=1), facial oedema (n=1) and lip sores (n=1). 
 
Seriousness was measured by the patients’ treatment outcome, as described in Table 3. The 
majority of the patients (n=7: 87.5%) required an intervention to prevent permanent 
impairment/damage. One did not require an intervention because the adverse drug reaction 
resolved on its own (Table 4). 
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Table 4: Seriousness of the reported adverse drug reactions 
 
N=8 
Seriousness of reported ADRs*** 
n=8 
Frequency n (%) 
Required intervention 7 (87.5) 
Symptoms improved without intervention 1 (12.5) 
Resulted in disability 0 (0) 
Life-threatening 0 (0) 
Patient demised 0 (0) 
 
 
Action taken regarding the adverse drug reactions 
Hydrocortisone injection was given to treat the patients who were shivering, had fever and a 
swollen arm while injecting amphoteracin B and the rash probably caused by amoxicillin. 
Aciclovir cream was used to treat lip sores probably caused by amphoteracin B. 
Metronidazole was changed from the oral formulation to injection to avoid vomiting. 
Lopinavir/ritonavir combination was changed to atazanavir to avoid vomiting. Fluids were 
given to flush out the tenofovir/emticitabine/efavirenz combination. The adverse drug 
reaction experienced by the patient on cefazolin resolved on its own and did not require 
intervention (Table 5). 
 
 
Table 5: Adverse drug reactions reported in relation to action taken 
 
Antibiotic Adverse drug reaction 
 
Action taken 
Amphoteracin B Shivering  Hydrocortisone injection 
 
Amphoteracin B Shivering, fever, swollen 
arm 
Hydrocortisone injection 
 
Amphoteracin B Lip sores Aciclovir cream 
 
Amoxicillin Rash  Hydrocortisone injection 
 
Cefazolin Facial oedema Did not require 
intervention 
 
Lopinavir/Ritonavir Vomiting Changed to Atazanavir 
 
Metronidazole Vomiting 
 
Changed from oral to 
injection 
Tenofovir/Emtricitrabine/Efavirenz Dizziness  Fluids 
 
21 
 
Discussion 
 
A total of 10 adverse drug reaction reports were collected of which 8 were related to 
antibiotic use. The small number of adverse drug reactions found in this study could be due to 
the size of the hospital, short time-frame in which the study was conducted, inclusion of 
inpatients only, or under-reporting.  
 
Antibiotic related adverse drug reactions constituted 80% of all adverse drug reactions 
identified in this study. This was significantly high and supports previous studies finding 
antibiotics contributing to most adverse drug reactions. Antibiotics are among the most 
commonly prescribed drugs in hospitals thereby increasing their rate of adverse drug 
reactions.  
 
In this study, amphoteracin B was the antibiotic associated with the highest incidence of 
adverse reactions reported. This can be due to the high plasma protein binding of 
amphotericin B as well as slow excretion via the kidneys. Amphoteracin B also has a narrow 
therapeutic index. Fever, shivering and swollen limbs are known adverse drug reactions of 
amphoteracin B that were also reported in adverse drug reaction reports in this study. Lip 
sores is an adverse drug reaction not previously recorded with the use of amphoteracin B. As 
this adverse drug reaction was not identified during clinical trials, it might help to compile the 
safety profile of amphoteracin B and hopefully be added onto the list of known adverse 
reactions under the drug labelling of Amphoteracin B.   
 
The other antibiotics for which adverse drug reaction reports were received e.g. amoxicillin, 
metronidazole, cefazolin, lopinavir/ritonavir combination and 
Tenofovir/Emtricitrabine/Efavienz combination, are prone to adverse drug reactions and the 
adverse drug reactions recorded in this study are all well documented. 
 
Females were found to be at a higher risk of developing adverse drug reactions compared to 
males, which could be attributed to physiological differences in the pharmacokinetics 
affecting antibiotics.  
 
In this study one patient was admitted as a direct result of an adverse drug reaction associated 
with antibiotic use; the other cases were hospitalized patients that developed adverse drug 
reactions related to antibiotics during their stay in hospital. Only one adverse drug reaction, 
associated with cefazolin, resolved on its own while all other cases required an intervention 
to prevent permanent disability and/or impairment. This highlights the importance of 
identifying adverse drug reactions and taking the necessary action to prevent patient 
morbidity and mortality. 
 
Previously, adverse drug reaction monitoring was rarely done in the study hospital and 
previous reporting only focused on outpatients receiving anti-retroviral treatment. This study 
used both active and passive methods of obtaining adverse drug reactions associated with 
antibiotic use. The importance of adverse drug reaction in a hospital setting was highlighted 
in this study because a new adverse drug reaction was identified and the occurrence of known 
adverse drug reactions was recorded. This will help health care professionals to initiate risk 
management plans that will minimize and prevent future preventable adverse drug reactions. 
South Africa uses a spontaneous reporting system in which health care professionals are 
responsible for reporting suspected adverse drug reactions. A comprehensive 
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pharmacovigilance system includes both active and passive surveillance methods and ensures 
efficient surveillance of adverse drug reactions. This study supports the need for adverse drug 
reaction monitoring and reporting, indicating that it is essential in a hospital setting so as to 
ensure the safety of drugs administered to patients by improving the quality of care, 
minimizing the length of hospital stay, health care costs and the interventions required. 
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Conclusion 
 
This study found significant adverse drug reactions associated with the use of antibiotics. 
Knowledge of the most prevalent adverse drug reactions, antibiotics involved, and population 
groups at risk can help decrease the incidence of adverse drug reactions associated with 
antibiotic use in all levels of health care in South Africa. The results of this study will 
hopefully encourage health care professionals to report adverse drug reactions, which will 
improve the quality of adverse drug reaction monitoring and reporting to ensure safer 
antibiotic use in hospitals. This will also help all health care professionals to reinforce the 
goals set out by the Department of Health to help strengthen strategies to maximize patient 
safety, ensure rational use of medicines, and reduce healthcare costs caused by adverse drug 
reactions at the primary level of healthcare.  
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CHAPTER 3 
CONCLUSIONS 
 
3.1 Introduction  
 
This study was carried out to evaluate the adverse drug reactions, associated with antibiotic use, in a 
public sector hospital.  
 
3.1.1 Strengths of the study methodology and design 
Data sets used in the study were obtained using adverse drug reaction reports therefore making data 
collection cost-effective.  
 
3.2 Conclusions drawn from the study findings 
The aim of this study was to evaluate adverse drug reactions associated with antibiotic use in a public 
sector hospital with reference to the antibiotics involved, adverse drug reactions in relation to patient 
demographics, types and seriousness of adverse drug reactions reported, and interventions required. 
To achieve this, the following specific objectives were outlined: 
 
 The number adverse drug reactions associated with antibiotic use was determined. 
 The antibiotic with the highest number of adverse drug reactions was identified.  
 Clinical profile of antibiotics including indication and route of administration. 
 Adverse drug reactions were classified according to severity. 
 Adverse drug reactions were classified according to action taken. 
 
Conclusions drawn from the study findings based on each of the objectives   
 
• Antibiotic related adverse drug reactions constituted 80% of all adverse drug reactions 
reported. This was significantly high and suggests that antibiotics contribute to most adverse 
drug reaction reports. Antibiotics are among the most commonly prescribed drugs in hospitals 
thereby increasing their rate of adverse drug reactions. This can also be attributed to the 
mechanism of action of the antibiotics involved. 
• The most commonly reported antibiotic associated with adverse drug reactions was 
Amphoteracin B (n=3; 37.5%). Amphoteracin B is highly bound onto plasma proteins and it 
is excreted slowly via the kidneys. Amphoteracin B furthermore has a narrow therapeutic 
index. Fever, shivering and swollen arm are known adverse drug reactions of amphoteracin B. 
Lip sores is a new adverse drug reaction seen with the use of amphoteracin B in this study. 
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• Intravenous route (n=5) was the most common route of administration of the antibiotics in 
this study and could have enhanced adverse drug reactions due to the immediate therapeutic 
effect. 
• The impact of adverse drug reactions associated with antibiotic use in the public hospital were 
serious in 2 cases, one required hospitalization and the other prolongation of hospital stay. 
This could have been attributed to the mechanism of action of the antibiotics involved. 
• A considerably high rate of patients n=7 (87.5%) required an intervention to prevent 
permanent disability and/or impairment. Patients that required an intervention (either a change 
in regimen, a supplementary drug or therapy to treat the adverse drug reaction) Only one 
adverse drug reaction associated resolved on its own. 
 
 
3.3 Significance of the study  
 
• The study will encourage health care professionals in the public sector to practice active and 
spontaneous adverse drug reaction reporting. This information will be useful for identifying 
and minimizing adverse drug reactions and may enhance the ability of prescribers to manage 
adverse drug reactions more effectively. 
 
• The study will contribute to the development of strategies for the pharmacovigilance service 
at the public sector hospital, which will improve the quality of adverse drug reaction 
monitoring and reporting to ensure safer drug use in the hospital. It will improve the 
classification and management of serious and non-serious adverse drug reactions in the public 
sector hospital. 
 
• This study will describe the experiences of adverse drug reactions related to antibiotics in a 
public sector hospital. 
 
 
3.4 Limitations of the study 
 
• Sample size: small due to a few adverse drug reactions reported during the study period and 
the focus only on hospital patients. 
 
• Incomplete or inaccurate reporting: A small proportion of adverse drug reactions being 
reported and reports containing limited information. Relevant data, such as underlying 
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medical conditions, concurrent medications, and temporal associations were absent. 
Information provided in adverse drug reaction reports was highly variable; some reports quite 
detailed, whereas others provided little data. 
 
• Bias  
 
o Population bias- the use of adverse drug reaction reports obtained from the public sector 
hospital only and data collected from hospital patients only. 
o Detection bias- it may have not be easy to classify an adverse drug reaction. A causal 
relationship between an antibiotic and event could have not been established. 
o Reporting bias- clinicians have different perceptions about specific drugs. Many factors 
can influence whether or not an event is reported 
 
• Time constraints: Short period (3 months) for the study. 
 
• Underreporting: clinicians fear that adverse drug reaction reporting means that they are 
incompetent.  
 
• The data obtained and used in this study was restricted to a public-sector hospital 
 
• The use of complementary and/or herbal medicines by these patients was not considered in 
this study. Only medicines that patients were receiving from the hospital were considered. 
Therefore, drug interactions amongst herbal/complementary medicines with antibiotics were 
not considered in terms of possibly causing the adverse drug reaction or influencing its 
outcome. 
 
 
3.5 Recommendations  
 
• Adverse drug reaction reports from both public-sector and private-sector can provide a 
broader insight when studying adverse drug reactions associated with antibiotic use. 
Therefore, further studies should incorporate both sectors.    
 
• Avoiding unnecessary antibiotic use reduces not only the public health threat of antibiotic 
resistance but also the risk of adverse drug reactions in individual patients, therefore 
appropriate use of antibiotics should be upheld. 
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• Further studies on the topic should take into consideration herbal/complementary medicines 
that patients use to treat concomitant diseases and their possible drug-drug interaction(s) with 
antibiotics as this could possibly influence the outcome of adverse drug reactions.  
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3.6 Chapter summary  
 
The final chapter highlighted the conclusions drawn from the findings of the study, described the 
strengths and limitations of the study, as well as provided recommendations for future research. 
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